Lars Erwig is the Cardiovascular and Metabolism Innovation Lead for Johnson & Johnson Innovation and is located at the Innovation Centre in London. In this role, he is responsible for growing the cardiovascular, metabolic, renal and retinal academic and industry network in EMEA and to identify and advance external opportunities.
Prior to joining Johnson & Johnson Innovation he worked for Galvani Bioelectronics (a GSK/Google-Verily funded company) where, as Vice President and Head of Experimental Medicine and Clinical Development , he was responsible for taking the emerging field of peripheral precision neuromodulation into human clinical trials in chronic autoimmune conditions. Prior to this, Lars was an early development lead at GSK in the Experimental Medicine Discovery Performance Unit Head within the immuno-inflammation therapy area, responsible for leading multidisciplinary teams to advance projects from candidate selection through to commit to medicine development.
Before joining the pharmaceutical industry he was a Professor of Nephrology at the University of Aberdeen. He is board certified in Nephrology and General Internal Medicine. He received his PhD from the University of Aberdeen and his MD from the Medizinische Hochschule Hannover.